Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2025-08-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司十届七次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 哈药集团股份有限公司 regarding the 2025 half-year report and related financial decisions such as asset impairment and asset write-offs. It includes the Supervisory Board's review and approval of the half-year report but does not contain the full financial statements or detailed financial data itself. The document length is short (885 characters) and it serves as an official announcement of the Supervisory Board's decisions and opinions rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal announcement related to regulatory compliance and supervisory board resolutions, not the full interim report (IR) or annual report (10-K).
2025-08-22 Chinese
哈药集团股份有限公司关于调整2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the adjustment of the estimated amount of daily related-party transactions for the year 2025. It details the approval process by the board, the specific adjustments in transaction amounts, the related parties involved, and the rationale behind the adjustments. The document is a formal announcement about changes in expected related-party transactions, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis but rather updates on operational estimates and governance approvals related to related-party transactions. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about related-party transaction adjustments without constituting a full report or financial statement.
2025-08-22 Chinese
哈药集团股份有限公司十届十六次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 regarding the decision to lease out some idle assets of a subsidiary. It details the board meeting date, attendance, voting results, and the decision made. There is no financial data, no mention of annual or interim reports, no audit information, and no regulatory certification. The document is an official announcement of a board decision, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement. Therefore, the classification is MANG with high confidence.
2025-08-04 Chinese
哈药集团股份有限公司关于公司分公司挂牌出租部分闲置资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 哈药集团股份有限公司 regarding the leasing of some idle assets of its subsidiary. It details the transaction overview, the assets involved, the leasing terms, and the expected impact on the company. There is no financial data, no quarterly or annual report content, no audit information, no management or board changes, no earnings release, no legal proceedings, no merger or acquisition activity, and no voting results. The document is a formal announcement about a specific asset leasing transaction and its terms, which fits best under a general regulatory announcement category. It is not a report or a presentation but a regulatory disclosure about a corporate transaction that does not require shareholder approval. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters and is a detailed announcement, not a report publication notice or certification letter, so RNS is the best fit with high confidence.
2025-08-04 Chinese
哈药集团股份有限公司关于控股股东股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of total shares, the purpose of the pledge, and the impact on the company. It does not contain financial statements or detailed financial performance data. The document is a regulatory announcement about share pledge activity, which fits the category of Capital/Financing Update (CAP). The document length is short and focused on a specific financing-related event, not a full report or audit. Therefore, the appropriate classification is CAP with high confidence.
2025-07-22 Chinese
哈药集团股份有限公司关于控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the partial release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the remaining pledged shares, and the reasons for the release related to refinancing. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal disclosure about share pledge status, which fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement about share pledging and does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short (1752 characters), and it is not a report or a presentation but an official announcement of share pledge status.
2025-07-04 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.